TG Therapeutics (TGTX) Stock Price, News & Analysis

Company Overview

TG Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing and delivering treatments for B-cell diseases and autoimmune disorders. The company’s research and development programs are centered on therapies that target B cells, which play an important role in several immune-mediated conditions.

TG Therapeutics’ principal product is BRIUMVI (ublituximab-xiiy), an anti-CD20 monoclonal antibody approved by the U.S. Food and Drug Administration for the treatment of adults with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting multiple sclerosis and active secondary progressive multiple sclerosis. BRIUMVI is administered by intravenous infusion and is designed to deplete certain B cells involved in the disease process.

The company commercializes BRIUMVI in the United States and continues to evaluate opportunities to expand access to its therapies internationally. TG Therapeutics has historically operated as a biotechnology company focused on oncology and immunology research, and its leadership includes Michael S. Weiss, who serves as executive chairman and chief executive officer.

Key Stats

• Today's Range: $56.56 to $58.62
• 50-Day Range: $46.17 to $58.11
• 52-Week Range: $26.76 to $59.30
• Volume: 2.03 million shs
• Average Volume: 1.72 million shs
• Market Capitalization: $8.89 billion
• P/E Ratio: 21.21
• Dividend Yield: N/A
• Price Target: $63.00
• Consensus Rating: Hold

TG Therapeutics Stock Analysis - MarketRank™

TG Therapeutics scored higher than 63% of companies evaluated by MarketBeat, and ranked 295th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.9 / 5
• Analyst Rating: Hold

Consensus Rating

TG Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.44, and is based on no strong buy ratings, 6 buy ratings, 1 hold rating, and 2 sell ratings.

Upside/Downside

The consensus price target for TG Therapeutics is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

TG Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 188.04%

Earnings Growth

Earnings for TG Therapeutics are expected to grow by 188.04% in the coming year, from $0.92 to $2.65 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of TG Therapeutics is 21.21, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.12.

Price to Earnings Ratio vs. Sector

The P/E ratio of TG Therapeutics is 21.21, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.31.

Price to Earnings Growth Ratio

TG Therapeutics has a PEG Ratio of 2.45. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

TG Therapeutics has a P/B Ratio of 14.24. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

21.60% of the float of TG Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

TG Therapeutics has a short interest ratio ("days to cover") of 15.86, which indicates bearish sentiment.

Change versus previous month

Short interest in TG Therapeutics has recently increased by 0.06%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

TG Therapeutics does not currently pay a dividend.

Dividend Growth

TG Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 1.00

News Sentiment

TG Therapeutics has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for TG Therapeutics this week, compared to 6 articles on an average week.

Search Interest

15 people have searched for TGTX on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.

MarketBeat Follows

Only 5 people have added TG Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, TG Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $274,800.00 in company stock.

Percentage Held by Insiders

8.87% of the stock of TG Therapeutics is held by insiders.

Percentage Held by Institutions

58.58% of the stock of TG Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/03/2026
• Today: 9/23/2026
• Next Earnings (Estimated): 11/02/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:TGTX
• Previous Symbol: OTCMKTS:TGTX
• CIK: 1001316
• Web: www.tgtherapeutics.com
• Phone: (212) 554-4484
• Fax: 212-554-4531
• Employees: 399
• Year Founded: 1993

Price Target and Rating

• Average Price Target for TG Therapeutics: $63.00
• High Price Target: $86.00
• Low Price Target: $20.00
• Potential Upside/Downside: +8.4%
• Consensus Rating: Hold
• Rating Score (0-4): 2.44
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): $2.74
• Trailing P/E Ratio: 21.21
• Forward P/E Ratio: 63.16
• P/E Growth: 2.45
• Net Income: $447.18 million
• Net Margins: 55.22%
• Pretax Margin: 12.71%
• Return on Equity: 73.49%
• Return on Assets: 34.14%

Debt

• Debt-to-Equity Ratio: 1.23
• Current Ratio: 4.27
• Quick Ratio: 3.72

Sales & Book Value

• Annual Sales: $616.29 million
• Price / Sales: 14.43
• Cash Flow: $2.85 per share
• Price / Cash Flow: 20.40
• Book Value: $4.08 per share
• Price / Book: 14.24

Miscellaneous

• Outstanding Shares: 153,070,000
• Free Float: 139,492,000
• Market Cap: $8.89 billion
• Optionable: Optionable
• Beta: 1.67